Sangamo Therapeutics Inc. (Nasdaq: SGMO)

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic™ development program is currently in Phase 2 clinical trials for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF™) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN™) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. A portion of Sangamo's research in plant agriculture is supported by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology. Sangamo has also established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. *

	Start	2018-07-23 renamed before
	Group	Sangamo (Group)
	Predecessor	Sangamo BioSciences Inc. (Nasdaq: SGMO)
	Industry	BIOTECH
	Person	Macrae, Sandy (Sangamo 201807 CEO)
	Person 2	Lee, Sung (MorphoSys 202102–202303 CFO before Sangamo + Gilead Sciences LEFT 3/23)

	Region	Richmond, CA
	Country	United States (USA)
	City	n. a.
		Address record changed: 2018-07-23

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-05-04